Cargando…

The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist

Innate immune complement activation generates the C3 and C5 protein cleavage products C3a and C5a, defined classically as anaphylatoxins. C3a activates C3aR, while C5a activates two receptors (C5aR1 and C5aR2) to exert their immunomodulatory activities. The non-peptide compound, SB290157, was origin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xaria X., Kumar, Vinod, Clark, Richard J., Lee, John D., Woodruff, Trent M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859635/ https://www.ncbi.nlm.nih.gov/pubmed/33551801 http://dx.doi.org/10.3389/fphar.2020.591398

Ejemplares similares

TLQP-21 is a low potency partial C3aR activator on human primary macrophages
por: Li, Xaria X., et al.
Publicado: (2023)

Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections
por: Muenstermann, Marcel, et al.
Publicado: (2019)

The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
por: Woodruff, Trent M., et al.
Publicado: (2020)

Combined Therapy of A(1)AR Agonists and A(2A)AR Antagonists in Neuroinflammation
por: Marucci, Gabriella, et al.
Publicado: (2021)

Down-Regulation of C3aR/C5aR Inhibits Cell Proliferation and EMT in Hepatocellular Carcinoma
por: Chen, Bendong, et al.
Publicado: (2020)

C3aR and C5aR1 act as key regulators of human and mouse β-cell function
por: Atanes, Patricio, et al.
Publicado: (2017)

The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
por: Wang, Yu, et al.
Publicado: (2019)

C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera
por: Silva de França, Felipe, et al.
Publicado: (2021)

Anaphylatoxin Receptors C3aR and C5aR1 Are Important Factors That Influence the Impact of Ethanol on the Adipose Secretome
por: McCullough, Rebecca L., et al.
Publicado: (2018)

Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking
por: Tamamis, Phanourios, et al.
Publicado: (2014)

Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation
por: Rana, Soumendra, et al.
Publicado: (2015)

Cheminformatics analysis of the AR agonist and antagonist datasets in PubChem
por: Hao, Ming, et al.
Publicado: (2016)

A Commentary On: “NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease”. A cautionary note regarding C3aR
por: Woodruff, Trent M., et al.
Publicado: (2015)

Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors
por: Colley, Caroline S., et al.
Publicado: (2017)

C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid
por: Hornum, Lars, et al.
Publicado: (2017)

Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
por: Beach, Callum, et al.
Publicado: (2023)

The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury
por: Brandolini, Laura, et al.
Publicado: (2019)

DEFECTIVE ENGRAFTMENT OF C3aR(-/-) HEMATOPOIETIC STEM PROGENITOR CELLS REVEALS A NOVEL ROLE OF THE C3a-C3aR AXIS IN BONE MARROW HOMING
por: Wysoczynski, Marcin, et al.
Publicado: (2009)

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
por: Leone, Robert D., et al.
Publicado: (2015)

Differential Contributions of the Complement Anaphylotoxin Receptors C5aR1 and C5aR2 to the Early Innate Immune Response against Staphylococcus aureus Infection
por: Horst, Sarah A., et al.
Publicado: (2015)

Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients
por: Emtenani, Shirin, et al.
Publicado: (2022)

α(7) Nicotinic Agonist AR-R17779 Protects Mice against 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis in a Spleen-Dependent Way
por: Grandi, Andrea, et al.
Publicado: (2017)

C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis
por: Zheng, Quan-you, et al.
Publicado: (2019)

Role of C5a and C5aR in doxorubicin-induced cardiomyocyte senescence
por: Wen, Yahui, et al.
Publicado: (2021)

Adenovirus-Mediated In Vivo Silencing of Anaphylatoxin Receptor C5aR
por: Sun, Lei, et al.
Publicado: (2006)

C3aR signaling and gliosis in response to neurodevelopmental damage in the cerebellum
por: Young, Kevin G., et al.
Publicado: (2019)

Determination of the optimal concentration and duration of C5aR antagonist application in an inflammatory model of human dental pulp cells
por: Hu, Junlong, et al.
Publicado: (2023)

Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis
por: Wang, Haitao A., et al.
Publicado: (2017)

The complement C3a-C3aR and C5a-C5aR pathways promote viability and inflammation of human retinal pigment epithelium cells by targeting NF-κB signaling
por: Luo, Shasha, et al.
Publicado: (2022)

Combined treatment with Sigma1R and A2AR agonists fails to inhibit cocaine self-administration despite causing strong antagonistic accumbal A2AR-D2R complex interactions: the potential role of astrocytes
por: Borroto-Escuela, Dasiel O., et al.
Publicado: (2023)

C3a-C3aR signaling is a novel modulator of skeletal homeostasis
por: Kuhn, Megan B., et al.
Publicado: (2023)

Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair
por: Kovtun, Anna, et al.
Publicado: (2017)

C3a Enhances the Formation of Intestinal Organoids through C3aR1
por: Matsumoto, Naoya, et al.
Publicado: (2017)

Cntnap4 partial deficiency exacerbates α-synuclein pathology through astrocyte–microglia C3-C3aR pathway
por: Zhang, Wenlong, et al.
Publicado: (2023)

(2S,4aR,3S,8aR,9R,10R)-1,4-Diallyl-2,3-diphenylperhydroquinoxaline
por: Chen, Fang, et al.
Publicado: (2008)

Correction to: C3aR signaling and gliosis in response to neurodevelopmental damage in the cerebellum
por: Young, Kevin G., et al.
Publicado: (2020)

C3aR plays both sides in regulating resistance to bacterial infections
por: Corcoran, Jesse A., et al.
Publicado: (2022)

Mechanism of activation and biased signaling in complement receptor C5aR1
por: Feng, Yuying, et al.
Publicado: (2023)

Corrigendum to: Determination of the optimal concentration and duration of C5aR antagonist application in an inflammatory model of human dental pulp cells
Publicado: (2023)

(3R,3aR,6R,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diyl dibenzoate
por: Piccialli, Vincenzo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7l8lfai7ugdn5n8tni6ud81g1a